Moderna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
The World Health Organization asked six African countries to be alert for possible Ebola infections, as Guinea on Feb. 16 reported new cases and Democratic Republic of Congo said its new infections were a resurgence of a previous outbreak.
The U.S. Department of Health and Human Services is partnering with Regeneron Pharmaceuticals Inc. to develop a treatment for the coronavirus, making the drugmaker the latest to join the race to develop a therapy.
China’s National Health Commission stated today that the coronavirus has infected 5,974 individuals, resulting in 132 deaths and 103 people being cured.
The U.S. Food and Drug Administration approved drugmaker Merck & Co.’s Ebola vaccine Ervebo, the first FDA-authorized vaccine against the deadly virus.
The world’s first Ebola vaccine was recommended for approval by European drug regulators in a move hailed by the World Health Organization (WHO) as a “triumph for public health.”
Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November 2019 in the country’s eastern provinces, to counter the current outbreak.
GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.
The U.S. Centers for Disease Control and Prevention (CDC) published research in the journal Lancet Infectious Diseases outlining the results from two experimental Ebola drugs, Gilead Sciences’ remdesivir and Mapp Biopharmaceutical’s ZMapp.
A global coalition set up to fight emerging epidemics struck a $31 million deal with scientists at Japan’s University of Tokyo to speed up work on a vaccine against a brain-damaging disease caused by the Nipah virus.